{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:42:52Z","timestamp":1791981772431,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P30105"],"award-info":[{"award-number":["P30105"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fonds of the City of Vienna for Innovative Cancer Research"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13046-017-0592-3","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T09:56:44Z","timestamp":1505123804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer"],"prefix":"10.1186","volume":"36","author":[{"given":"Bernhard","family":"Englinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kallus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Senkiv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Heilos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Gabler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushilla","family":"van Schoonhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Terenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Pirker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Timelthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian R.","family":"Kowol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Heffeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,7]]},"reference":[{"key":"592_CR1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/med.21288","volume":"34","author":"M Katoh","year":"2014","unstructured":"Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34:280\u2013300.","journal-title":"Med Res Rev"},{"key":"592_CR2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116\u201329.","journal-title":"Nat Rev Cancer"},{"key":"592_CR3","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1517\/14728222.2011.566217","volume":"15","author":"C Heinzle","year":"2011","unstructured":"Heinzle C, Sutterluty H, Grusch M, Grasl-Kraupp B, Berger W, Marian B. Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. Expert Opin Ther Targets. 2011;15:829\u201346.","journal-title":"Expert Opin Ther Targets"},{"key":"592_CR4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semcdb.2015.10.012","volume":"53","author":"Y Tanner","year":"2016","unstructured":"Tanner Y, Grose RP. Dysregulated FGF signalling in neoplastic disorders. Semin Cell Dev Biol. 2016;53:126\u201335.","journal-title":"Semin Cell Dev Biol"},{"key":"592_CR5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/1566524016666151222144231","volume":"16","author":"S Saichaemchan","year":"2016","unstructured":"Saichaemchan S, Ariyawutyakorn W, Varella-Garcia M. Fibroblast growth factor receptors: from the Oncogenic pathway to targeted therapy. Curr Mol Med. 2016;16:40\u201362.","journal-title":"Curr Mol Med"},{"key":"592_CR6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22:259\u201367.","journal-title":"Clin Cancer Res"},{"key":"592_CR7","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","volume":"21","author":"M Touat","year":"2015","unstructured":"Touat M, Ileana E, Postel-Vinay S, Andre F, Soria JC. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015;21:2684\u201394.","journal-title":"Clin Cancer Res"},{"key":"592_CR8","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.1158\/0008-5472.CAN-11-3654","volume":"72","author":"C Heinzle","year":"2012","unstructured":"Heinzle C, Gsur A, Hunjadi M, Erdem Z, Gauglhofer C, Stattner S, Karner J, Klimpfinger M, Wrba F, Reti A, et al. Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis. Cancer Res. 2012;72:5767\u201377.","journal-title":"Cancer Res"},{"key":"592_CR9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.semcdb.2015.12.014","volume":"53","author":"X Li","year":"2016","unstructured":"Li X, Wang C, Xiao J, McKeehan WL, Wang F. Fibroblast growth factors, old kids on the new block. Semin Cell Dev Biol. 2016;53:155\u201367.","journal-title":"Semin Cell Dev Biol"},{"key":"592_CR10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","volume":"38","author":"M Katoh","year":"2016","unstructured":"Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review). Int J Mol Med. 2016;38:3\u201315.","journal-title":"Int J Mol Med"},{"key":"592_CR11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.tips.2016.10.003","volume":"37","author":"M Katoh","year":"2016","unstructured":"Katoh M. Therapeutics targeting FGF signaling network in human diseases. Trends Pharmacol Sci. 2016;37:1081\u201396.","journal-title":"Trends Pharmacol Sci"},{"key":"592_CR12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.03.015","volume":"46","author":"N Hallinan","year":"2016","unstructured":"Hallinan N, Finn S, Cuffe S, Rafee S, O'Byrne K, Gately K. Targeting the fibroblast growth factor receptor family in cancer. Cancer Treat Rev. 2016;46:51\u201362.","journal-title":"Cancer Treat Rev"},{"key":"592_CR13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/1753465815579608","volume":"9","author":"C Caglevic","year":"2015","unstructured":"Caglevic C, Grassi M, Raez L, Listi A, Giallombardo M, Bustamante E, Gil-Bazo I, Rolfo C. Nintedanib in non-small cell lung cancer: from preclinical to approval. Ther Adv Respir Dis. 2015;9:164\u201372.","journal-title":"Ther Adv Respir Dis"},{"key":"592_CR14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/jm501562a","volume":"58","author":"GJ Roth","year":"2015","unstructured":"Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL, Kaiser R. Nintedanib: from discovery to the clinic. J Med Chem. 2015;58:1053\u201363.","journal-title":"J Med Chem"},{"key":"592_CR15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1758834016630976","volume":"8","author":"G Bronte","year":"2016","unstructured":"Bronte G, Passiglia F, Galvano A, Barraco N, Listi A, Castiglia M, Rizzo S, Fiorentino E, Bazan V, Russo A. Nintedanib in NSCLC: evidence to date and place in therapy. Ther Adv Med Oncol. 2016;8:188\u201397.","journal-title":"Ther Adv Med Oncol"},{"key":"592_CR16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"L Nogova","year":"2017","unstructured":"Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 Kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol. 2017;35:157\u201365.","journal-title":"J Clin Oncol"},{"key":"592_CR17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jchromb.2016.04.049","volume":"1023-1024","author":"RW Sparidans","year":"2016","unstructured":"Sparidans RW, Kort A, Schinkel AH, Schellens JH, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1023-1024:24\u20139.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"592_CR18","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/jcph.752","volume":"56","author":"C Dallinger","year":"2016","unstructured":"Dallinger C, Trommeshauser D, Marzin K, Liesener A, Kaiser R, Stopfer P. Pharmacokinetic properties of Nintedanib in healthy volunteers and patients with advanced cancer. J Clin Pharmacol. 2016;56:1387\u201394.","journal-title":"J Clin Pharmacol"},{"key":"592_CR19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jchromb.2015.08.032","volume":"1002","author":"XW Xu","year":"2015","unstructured":"Xu XW, Su XJ, Zhang YN, Zheng XK, Lv PF, Hu J. Simultaneous determination of nintedanib and its metabolite BIBF 1202 in different tissues of mice by UPLC-MS\/MS and its application in drug tissue distribution study. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;1002:239\u201344.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"592_CR20","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","volume":"72","author":"PR Gavine","year":"2012","unstructured":"Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, et al. AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72:2045\u201356.","journal-title":"Cancer Res"},{"key":"592_CR21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nchem.1961","volume":"6","author":"D Fu","year":"2014","unstructured":"Fu D, Zhou J, Zhu WS, Manley PW, Wang YK, Hood T, Wylie A, Xie XS. Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering. Nat Chem. 2014;6:614\u201322.","journal-title":"Nat Chem"},{"key":"592_CR22","doi-asserted-by":"crossref","first-page":"16486","DOI":"10.1039\/C5CC06983A","volume":"51","author":"RF Lee","year":"2015","unstructured":"Lee RF, Escrig S, Croisier M, Clerc-Rosset S, Knott GW, Meibom A, Davey CA, Johnsson K, Dyson PJ. NanoSIMS analysis of an isotopically labelled organometallic ruthenium(II) drug to probe its distribution and state in vitro. Chem Commun (Camb). 2015;51:16486\u20139.","journal-title":"Chem Commun (Camb)"},{"key":"592_CR23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.15586\/jkcvhl.2015.44","volume":"2","author":"K Azijli","year":"2015","unstructured":"Azijli K, Gotink KJ, Verheul HM. The potential role of Lysosomal sequestration in Sunitinib resistance of renal cell cancer. J Kidney Cancer VHL. 2015;2:195\u2013203.","journal-title":"J Kidney Cancer VHL"},{"key":"592_CR24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1124\/mol.114.097451","volume":"88","author":"H Burger","year":"2015","unstructured":"Burger H, den Dekker AT, Segeletz S, Boersma AW, de Bruijn P, Debiec-Rychter M, Taguchi T, Sleijfer S, Sparreboom A, Mathijssen RH, Wiemer EA. Lysosomal sequestration determines intracellular Imatinib levels. Mol Pharmacol. 2015;88:477\u201387.","journal-title":"Mol Pharmacol"},{"key":"592_CR25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejps.2017.04.016","volume":"105","author":"P Sieger","year":"2017","unstructured":"Sieger P, Cui Y, Scheuerer S. pH-dependent solubility and permeability profiles: A useful tool for prediction of oral bioavailability. Eur J Pharm Sci. 2017;105:82\u201390.","journal-title":"Eur J Pharm Sci."},{"key":"592_CR26","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00249-008-0338-4","volume":"37","author":"S Trapp","year":"2008","unstructured":"Trapp S, Rosania GR, Horobin RW, Kornhuber J. Quantitative modeling of selective lysosomal targeting for drug design. Eur Biophys J. 2008;37:1317\u201328.","journal-title":"Eur Biophys J"},{"key":"592_CR27","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.freeradbiomed.2016.04.201","volume":"96","author":"N Seebacher","year":"2016","unstructured":"Seebacher N, Lane DJ, Richardson DR, Jansson PJ. Turning the gun on cancer: utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance. Free Radic Biol Med. 2016;96:432\u201345.","journal-title":"Free Radic Biol Med"},{"key":"592_CR28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/35067100","volume":"2","author":"CB Thien","year":"2001","unstructured":"Thien CB, Langdon WY. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol. 2001;2:294\u2013307.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"592_CR29","first-page":"45","volume":"286","author":"A Wiedlocha","year":"2004","unstructured":"Wiedlocha A, Sorensen V. Signaling, internalization, and intracellular activity of fibroblast growth factor. Curr Top Microbiol Immunol. 2004;286:45\u201379.","journal-title":"Curr Top Microbiol Immunol"},{"key":"592_CR30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","volume":"24","author":"B Zhitomirsky","year":"2016","unstructured":"Zhitomirsky B, Assaraf YG. Lysosomes as mediators of drug resistance in cancer. Drug Resist Updat. 2016;24:23\u201333.","journal-title":"Drug Resist Updat"},{"key":"592_CR31","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.tiv.2010.12.010","volume":"25","author":"S Nadanaciva","year":"2011","unstructured":"Nadanaciva S, Lu S, Gebhard DF, Jessen BA, Pennie WD, Will Y. A high content screening assay for identifying lysosomotropic compounds. Toxicol in Vitro. 2011;25:715\u201323.","journal-title":"Toxicol in Vitro"},{"key":"592_CR32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.phrs.2016.12.021","volume":"117","author":"OF Kuzu","year":"2017","unstructured":"Kuzu OF, Toprak M, Noory MA, Robertson GP. Effect of lysosomotropic molecules on cellular homeostasis. Pharmacol Res. 2017;117:177\u201384.","journal-title":"Pharmacol Res"},{"key":"592_CR33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul. 1984;22:27\u201355.","journal-title":"Adv Enzym Regul"},{"key":"592_CR34","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1517\/13543776.2011.561784","volume":"21","author":"N Akhtar","year":"2011","unstructured":"Akhtar N, Ahad A, Khar RK, Jaggi M, Aqil M, Iqbal Z, Ahmad FJ, Talegaonkar S. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opin Ther Pat. 2011;21:561\u201376.","journal-title":"Expert Opin Ther Pat"},{"key":"592_CR35","doi-asserted-by":"crossref","first-page":"C723","DOI":"10.1152\/ajpcell.00462.2010","volume":"300","author":"KW Dunn","year":"2011","unstructured":"Dunn KW, Kamocka MM, McDonald JH. A practical guide to evaluating colocalization in biological microscopy. Am J Physiol Cell Physiol. 2011;300:C723\u201342.","journal-title":"Am J Physiol Cell Physiol"},{"key":"592_CR36","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1529\/biophysj.103.038422","volume":"86","author":"SV Costes","year":"2004","unstructured":"Costes SV, Daelemans D, Cho EH, Dobbin Z, Pavlakis G, Lockett S. Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys J. 2004;86:3993\u20134003.","journal-title":"Biophys J"},{"key":"592_CR37","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555\u201377.","journal-title":"Br J Cancer"},{"key":"592_CR38","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-13-3060","volume":"20","author":"MW Wynes","year":"2014","unstructured":"Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Bohm D, Perner S, Helfrich BA, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res. 2014;20:3299\u2013309.","journal-title":"Clin Cancer Res"},{"key":"592_CR39","doi-asserted-by":"crossref","first-page":"50161","DOI":"10.18632\/oncotarget.10324","volume":"7","author":"B Englinger","year":"2016","unstructured":"Englinger B, Lotsch D, Pirker C, Mohr T, van Schoonhoven S, Boidol B, Lardeau CH, Spitzwieser M, Szabo P, Heffeter P, et al. Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-a receptor-activated ABCB1 expression. Oncotarget. 2016;7:50161\u201379.","journal-title":"Oncotarget"},{"key":"592_CR40","doi-asserted-by":"crossref","first-page":"17707","DOI":"10.1016\/S0021-9258(19)47429-2","volume":"266","author":"T Yoshimori","year":"1991","unstructured":"Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem. 1991;266:17707\u201312.","journal-title":"J Biol Chem"},{"key":"592_CR41","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/0006-2952(74)90174-9","volume":"23","author":"C Duve de","year":"1974","unstructured":"de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. Commentary. Lysosomotropic agents. Biochem Pharmacol. 1974;23:2495\u2013531.","journal-title":"Biochem Pharmacol"},{"key":"592_CR42","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.18632\/oncotarget.2732","volume":"6","author":"B Zhitomirsky","year":"2015","unstructured":"Zhitomirsky B, Assaraf YG. Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance. Oncotarget. 2015;6:1143\u201356.","journal-title":"Oncotarget"},{"key":"592_CR43","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/emboj.2012.32","volume":"31","author":"C Settembre","year":"2012","unstructured":"Settembre C, Zoncu R, Medina DL, Vetrini F, Erdin S, Erdin S, Huynh T, Ferron M, Karsenty G, Vellard MC, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 2012;31:1095\u2013108.","journal-title":"EMBO J"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-017-0592-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T16:18:30Z","timestamp":1659457110000},"score":1,"resource":{"primary":{"URL":"http:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-017-0592-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1186\/s13046-017-0592-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,7]]},"article-number":"122"}}